Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up

Melinda A Pruis,G D Marijn Veerman, H Carlijne Hassing,Daan A C Lanser,Marthe S Paats,Ron H N van Schaik,Ron H J Mathijssen,Olivier Manintveld,Anne-Marie C Dingemans

JACC: CardioOncology（2023）

引用 3|浏览12

暂无评分

摘要

No patients showed signs of a diminished left ventricular ejection fraction. Alectinib caused more bradycardia than previously reported (42%) with some instances of severe symptomatic bradycardia. Patients with severe toxicity generally had an elevated exposure above the therapeutic threshold.

查看译文

关键词

alectinib,anaplastic lymphoma kinase,bradycardia,cardio-oncology,non-small cell lung cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要